A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies

Trial Profile

A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs NIS 793 (Primary) ; Spartalizumab (Primary)
  • Indications Breast cancer; Colorectal cancer; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 Jun 2018 Planned End Date changed from 13 Jan 2020 to 13 Apr 2021.
    • 18 Jun 2018 Planned primary completion date changed from 13 Jan 2020 to 13 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top